Stockscreener 앱 받기
109.84
1.46%
1.58
시간 외 거래:
109.00
-0.84
-0.76%
Rhythm Pharmaceuticals Inc 주식(RYTM)의 최신 뉴스
Rhythm Pharmaceuticals highlights obesity pipeline, shares track sector peers - Ad-hoc-news.de
Rhythm Pharmaceuticals Stock On Fire: Up 26% With 10-Day Winning Streak - Trefis
Rhythm Pharmaceuticals 8-K Filing June 2026 – Company Details, Nasdaq Listing, and Executive Information - Minichart
Form 4 Rhythm Pharmaceuticals Inc For: 25 June By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals (RYTM) director receives RSUs, options and converts 4,712 RSUs - Stock Titan
[Form 4] RHYTHM PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
Director at Rhythm Pharmaceuticals (RYTM) receives new RSUs, options and exercises units - Stock Titan
Rhythm Pharmaceuticals (RYTM) director granted RSUs, stock options and converts RSUs to shares - Stock Titan
Rhythm Pharmaceuticals (RYTM) director granted RSUs, options and new shares - Stock Titan
Rhythm Pharmaceuticals (NASDAQ: RYTM) holders approve directors, pay and Ernst & Young - Stock Titan
Rhythm Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:RYTM) - TradingView
RYTM Forecast — Price Target — Prediction for 2027 - TradingView
Rhythm Pharmaceuticals(RYTM.US) Director Sells US$3.71 Million in Common Stock - Moomoo
Rhythm Pharmaceuticals (RYTM) director exercises options and sells 37,000 shares - Stock Titan
8-Day Rally Sends Rhythm Pharmaceuticals Stock Up 24% - Trefis
Rhythm Pharmaceuticals (RYTM) Stock Could Be 30.6% Undervalued on Its Growth Narrative - Sahm
Rhythm Pharmaceuticals stock surges 4.98% as RhythmPharma announces Dr. Shoemaker joins as Senior Medical Director - Traders Union
Form 144 RHYTHM PHARMACEUTICALS For: 22 June By Investing.com - Investing.com South Africa
[144] RHYTHM PHARMACEUTICALS, INC. SEC Filing - Stock Titan
Can Rhythm Pharmaceuticals (RYTM) ’s New Data Help Patients With a Rare Hunger Disorder? - Insider Monkey
Rhythm Pharmaceuticals Inc (RYTM) Institutional Confidence - TradingKey
A Quick Look at Today's Ratings for Rhythm Pharmaceuticals(RYTM.US), With a Forecast Between $105 to $155 - Moomoo
CCORF Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Raises Target Price to $151 - Moomoo
Rhythm Pharmaceuticals Inc (RYTM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Rhythm Pharmaceuticals, Inc. (RYTM) reports Q1 loss, tops revenue estimates - MSN
Rhythm Pharmaceuticals Inc (RYTM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Rhythm Pharmaceuticals Inc (RYTM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Rhythm Pharmaceuticals Inc - TradingKey
Rhythm Pharmaceuticals stock price target reiterated at $130 by TD Cowen By Investing.com - Investing.com South Africa
RYTM Stock Climbs As PWS Data Drive Analyst Upgrades - StocksToTrade
Palatin Technologies Is Pursuing the Next Generation of MC4R. Rhythm Just Reinforced Why That Matters - Benzinga
(RYTM) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Rhythm Pharmaceuticals Inc (RYTM) Valuation: PE, PB & Fair Value Analysis - TradingKey
Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Positive Interim Results from Phase 2 Setmelanotide Trial in Prader-Willi SyndromeSlideshow (NASDAQ:RYTM) 2026-06-17 - Seeking Alpha
RYTM News | RHYTHM PHARMACEUTICALS INC (NASDAQ:RYTM) - ChartMill
Rhythm Pharmaceuticals Inc (RYTM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Rhythm Pharmaceuticals Inc (RYTM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Rhythm Pharmaceuticals Inc (RYTM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Rhythm Pharmaceuticals stock price target reiterated at $130 by TD Cowen - Investing.com South Africa
TD Cowen Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $130 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Rhythm Pharmaceuticals posts long-term setmelanotide data for obesity - Yahoo! Finance Canada
Canaccord raises Rhythm Pharmaceuticals price target on trial data By Investing.com - Investing.com South Africa
Rhythm Pharmaceuticals: Buy Rating Reaffirmed as Strong PWS Data Lift 2033 Outlook and Price Target Raised to $151 from $143 - TipRanks
Canaccord raises Rhythm Pharmaceuticals price target on trial data - Investing.com
Citizens reiterates Rhythm Pharmaceuticals stock rating on bivamelagon data - Investing.com
Citizens reiterates Rhythm Pharmaceuticals stock rating on bivamelagon data By Investing.com - Investing.com Canada
How New Prader‑Willi Phase 2 Setmelanotide Data At Rhythm Pharmaceuticals (RYTM) Has Changed Its Investment Story - Sahm
Rhythm presents data on obesity treatments at endocrine meeting - Investing.com UK
Rhythm presents data on obesity treatments at endocrine meeting By Investing.com - Investing.com South Africa
Rhythm builds case for Phase III in Prader-Willi - biocentury.com
How This Biotech Is Taking On Genetic Obesity — And Winning - Investor's Business Daily
Rhythm Showcases Positive Setmelanotide Data Across Obesity Trials - TipRanks
Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026 - The Manila Times
Rhythm Pharmaceuticals (RYTM) reports strong MC4R obesity data across PWS, HO and BBS at ENDO 2026 - Stock Titan
Rhythm Pharmaceuticals Announces Multiple New Data Presentations From Mc4r Agonists - TradingView
Rhythm Pharma shares rise after positive 6-mont... | Pluang – Crypto, Stocks, Gold & Funds - Pluang
Why Is Rhythm Pharma Stock Jumping Today? - Benzinga
Stifel reiterates Rhythm Pharmaceuticals stock rating on PWS data By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: Promising Upside Amidst Strong Buy Ratings - DirectorsTalk Interviews
Rhythm trial finds up to 38% BMI drop in complex rare obesity cases - Stock Titan
Rhythm Pharmaceuticals (RYTM) Announces Positive Phase 2 Trial R - GuruFocus
1.36%
자본화:
|
볼륨(24시간):